Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06260774 · ClinicalTrials.gov registry record · Phase 1
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by TransCode Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT06260774: Active Phase 1 study of Advanced Solid Tumor, sponsored by TransCode Therapeutics.
NCT06260774 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by TransCode Therapeutics. The registered enrollment target is 16 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06260774, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by TransCode Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors
Primary Outcome
The safety and tolerability of escalating dose levels of TTX-MC138 to determine incidence of treatment-emergent adverse events (TEAEs).
Conditions Studied
Interventions
- DRUG TTX-MC138
Study Locations (4)
Texas
- Mary Crowley Cancer Center - Dallas
- MD Anderson Cancer Center - Houston
Utah
- START Mountain Region - West Valley City
Virginia
- Next Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-09-05 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 1 |
What the registry record for NCT06260774 still lists
NCT06260774 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which TTX-MC138 is the first listed.
NCT06260774 reports a single indexed study location in Texas, Utah, Virginia.
Frequently Asked Questions
What is clinical trial NCT06260774 about?
NCT06260774 is a clinical study titled "Study of TTX-MC138 in Subjects With Advanced Solid Tumors". A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors
What is the current status of trial NCT06260774?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2024-09-05. Estimated completion is 2027-02-01.
What conditions does trial NCT06260774 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06260774?
The interventions under investigation include: TTX-MC138 (DRUG).
Who is sponsoring clinical trial NCT06260774?
This trial is sponsored by TransCode Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06260774 being conducted?
This trial has 4 study locations across Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06260774's enrollment target sits among peer trials
16 183rd of 189 higher than 7 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI